Neonatal Fc receptor blockade by efgartigimod to help inflammatory nerve disease
Official title: Elucidating Novel Immunomodulatory Mechanisms of Neonatal Fc Receptor Blockade by Efgartigimod in a T Cell-Mediated Demyelinating Neuropathy Model
Funded at University of Texas Hlth Sci Ctr Houston · NIH-11453598 · Data updated 2026-11-12
Aims to test how blocking a specific antibody trafficking receptor with efgartigimod could improve nerve inflammation in a model of AIDP/GBS-type neuropathy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 3, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $234,000 |
| NIH project number | 1R21NS146824-01A1 |
| Project ID | NIH-11453598 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with inflammatory demyelinating neuropathies or clinicians seeking new therapeutic approaches for AIDP/GBS and CIDP.
✕Less likely to help
Patients with non-inflammatory neuropathies or unrelated conditions may not benefit from these findings.
What this research studies
This project uses an animal model of autoimmune demyelinating neuropathy to explore how efgartigimod, a drug that boosts IgG clearance, affects immune cells such as T cells and macrophages that damage nerve myelin. The study will examine how FcRn inhibition changes immune signaling and myelin protection, potentially uncovering broader immunomodulatory effects beyond autoantibody removal. Results could point to new ways to reduce nerve injury and improve recovery for patients with inflammatory neuropathies. The work is focused on mechanisms and treatment ideas rather than immediate clinical testing.
Why it matters
Potential benefit: If successful, the findings could guide future therapies that lessen nerve damage and improve outcomes for people with inflammatory demyelinating polyneuropathies.
How similar studies have gone: Previous work shows FcRn blockade can modulate immune responses and has clinical benefit in CIDP, supporting potential applicability to related neuropathies.
Where this research is happening
-
University of Texas Hlth Sci Ctr Houston
Houston, United States Active
Researchers
- Principal investigator: Zhang, Gang — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Zhang, Gang
Related research
Other NIH-funded projects on the same topics.
-
Non-invasive, microscopic biomarkers to detect CIPN in chemotherapy patients
This grant aims to develop a non-invasive imaging method to measure nerve changes in patients undergoing chemotherapy to better understand and monitor chemotherapy-induced peripheral neuropathy (CIPN).
-
Schwann cell aging and secretions linked to diabetic nerve damage
A research project looking at how aging nerve cells and their secretions may drive nerve damage in people with type 2 diabetes.
-
Diabetic bladder problems in diabetes mice show sex-specific nerve and inflammation roles
Aims to understand why bladder problems happen in diabetes, exploring how inflammation and nerves differ between male and female mice.
-
Prenyltransferase inhibitor as a new therapy for inflammatory neuropathy
A new drug candidate called FGTI-2734 is being studied to calm nerve inflammation in conditions like AIDP/Guillain-Barré syndrome, with the goal of protecting nerves and reducing symptoms.
-
KCTD11-related CMT neuropathy: uncovering how it damages nerves
We are studying a genetic form of Charcot–Marie–Tooth disease to understand what goes wrong in nerves and support future treatments.
-
Arginase-positive monocytes help protect optic nerve cells after eye injury
A study at a major university will explore how certain immune cells in the eye might protect retinal cells after traumatic injury or inflammation, aiming to turn inflammation into healing rather than damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.